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Screening for Neonatal Hyperbilirubinemia—First Do No Harm?
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Screening of newborn infants for hyperbilirubinemia (NHB) is a common clinical practice 
in the United States. Since 2004, the American Academy of Pediatrics has endorsed either 
universal or risk-based predischarge screening of bilirubin levels in newborns of 35 weeks’ 
gestational age or older to evaluate the risk for NHB using a nomogram standardized to age 
in hours and follow-up management using consensus-based treatment guidelines.1 The 
anticipated benefits of screening for NHB, followed by phototherapy and/or exchange 
transfusion when indicated, are to prevent acute bilirubin encephalopathy, which has a direct 
burden of morbidity and can also progress to chronic bilirubin encephalopathy (CBE) with 
devastating neurodevelopmental consequences (also known as kernicterus). However, it is 
important to consider the balance of benefits and harms of screening and treatment; newly 
published evidence2 that treatment of NHB is associated with elevated risks of epilepsy 
might lead hospitals to reevaluate the balance of benefits and risks of referring newborns for 
phototherapy on the basis of screening for NHB.
Although phototherapy is known to be effective in reducing serum bilirubin levels, the 
efficacy of phototherapy in reducing the incidence of kernicterus remains unquantified. 
Further, phototherapy is associated with harms. Two US organizations have concluded that 
there was insufficient evidence to warrant universal screening of term or near-term infants 
for NHB as a clinical practice guideline: the US Preventive Services Task Force in 20093 
and the American Academy of Family Physicians (AAFP) in 2014.4 The AAFP cited 
unsupported reports of associations of neonatal jaundice with asthma and type 1 diabetes as 
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evidence of potential long-term risks of phototherapy. The AAFP also cited evidence that 
universal screening for NHB is associated with frequent inappropriate use of phototherapy 
for infants who do not meet clinical guidelines for treatment.
In addition, the Advisory Committee on Heritable Disorders in Newborns and Children 
(ACHDNC) in 2012 considered whether to recommend that NHB be added to the US 
Department of Health and Human Services Recommended Uniform Screening Panel for 
mandated public health newborn screening.5 The ACHDNC follows a decision matrix that 
includes consideration of evidence of both benefits and harms of screening and treatment. 
The ACHDNC decided not to recommend that screening for NHB be added to the 
Recommended Uniform Screening Panel, based on the lack of direct evidence that screening 
reduces the occurrence of CBE. The evidence review6 conducted for the ACHDNC 
acknowledged evidence of minor (temporary) harms associated with phototherapy but 
identified no evidence of long-term harms. The review noted that a 6-year follow-up of a 
randomized clinicaltrial7 of phototherapy for NHB by the National Institutes for Child 
Health and Development found no differences in developmental outcomes. However, since 
only 335 children who received phototherapy were examined at 6 years, the study was not 
powered to evaluate risks of uncommon neurological sequelae.
Although cohort studies conducted at Kaiser Permanente of Northern California (KPNC) 
found no associations of phototherapy with the long-term harms of either type 1 diabetes or 
asthma, KPNC research2 did confirm a previous finding from Denmark8 that phototherapy 
for NHB was associated with significantly increased risk of epilepsy in boys, although not 
girls. The KPNC study2 of prospectively gathered data for a cohort of a half million children 
born at term or near term, of whom 37 683 received phototherapy, found a crude epilepsy 
hazard ratio of 1.55 (95% CI, 0.83–2.66), similar to that reported in the Danish study. After 
adjusting for serum bilirubin levels and other potential confounders (eg, race/ ethnicity, 
gestational age, birth weight, other diagnoses), the adjusted hazard ratio for a diagnosis of a 
seizure disorder plus receipt of antiepileptic medication was reduced to 1.22 (95% CI, 1.05–
1.42) for all children; among boys alone, it was 1.33 (95% CI, 1.10–1.61). The authors2 
noted that the findings were consistent with sex differences in susceptibility to perinatal 
injury, as well as induced epilepsy in laboratory animals. However, they noted that they 
could not exclude the possibility of confounding by unobserved factors that might be 
associated with both phototherapy in early childhood and later seizures.
A relevant question for screening policy and practice is the balance of benefits and harms 
associated with treatments after screening. Newman and colleagues2 reported a “small 
increased risk of childhood seizures,”2 with an absolute excess 10-year risk of epilepsy of 
2.4 per 1000 children treated with phototherapy, with epilepsy assessed as the presence of 1 
or more encounter for nonfebrile seizures together with 1 or more filled prescription for an 
antiepileptic medication. Although the absolute risk of epilepsy is small, it is large relative to 
the number of potentially preventable cases of kernicterus. The findings imply that in a 
hypothetical cohort of 1 000 000 infants, of whom 76 000 receive phototherapy, 182 children 
will develop epilepsy as a result of treatment. The risk of kernicterus was estimated in the 
ACHDNC evidence review to be 0.47 to 1.30 per 100 000 newborns without screening, and 
the incidence of kernicterus with screening is estimated by KPNC researchers to be 0.57 per 
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100 000 newborns.9 That implies screening 1 000 000 infants for NHB and treatment could 
prevent up to 7 cases of kernicterus. Since many infants receive phototherapy for jaundice in 
the absence of screening, only a subset of the 182 cases of epilepsy could be attributed to the 
indirect effect of screening for NHB. Although CBE is more devastating than epilepsy and 
the association of phototherapy with epilepsy requires further study, the balance of benefit to 
risk is not clearly favorable to phototherapy for all infants diagnosed with NHB through 
screening.
One implication is that changes in treatment and bilirubin testing protocols that reduce the 
number of children who receive phototherapy could reduce the risk of harm without 
necessarily reducing the number of children who benefit clinically. Consistent with this 
approach, Newman et al2 suggest that restricting the number of children who receive 
phototherapy based on elevated bilirubin levels could greatly reduce the risk of harm. In 
particular, the KPNC data9 suggest that the risk of kernicterus may be limited to infants 
whose bilirubin levels are substantially higher than currently recommended thresholds and 
who also have other risk factors for neurotoxicity. Another way to reduce the overall number 
of children who receive phototherapy without excluding those who would be more likely to 
benefit could be to limit bilirubin testing to infants with clinical signs, chiefly jaundice. 
Infants born in KPNC hospitals after universal bilirubin testing was introduced were more 
likely to receive phototherapy than infants born in those hospitals previously and were less 
likely to be referred for exchange transfusion.10
The National Institutes for Child Health and Development phototherapy follow-up study was 
not powered to evaluate rare adverse outcomes, such as epilepsy. That is a cautionary lesson 
for policy makers: absence of evidence of harm is not evidence of absence of harm. Large-
scale, long-term follow-up studies of outcomes of screening and treatment are important to 
ensure that the anticipated positive balance of benefits and harms of newborn screening is 
realized in practice.
In conclusion, the stances of the AAFP, ACHDNC, and the US Preventive Services Task 
Force, which do not endorse universal screening for NBH, are reinforced by emerging data 
on the apparent risk of long-term harm of phototherapy associated with hyperbilirubinemia. 
These views are also reinforced by the persistent lack of clarity regarding which infants are 
at risk of developing CBE and the lack of direct evidence that screening reduces the risk of 
CBE.
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